Treatment for Cancer

Phase-Based Progress Estimates
Ascension Providence Rochester Hospital, Rochester, MICancer
All Sexes
What conditions do you have?

Study Summary

This trial will help researchers understand if the study treatment is effective and what side effects there may be.

Eligible Conditions
  • Metastatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 3 years

3 years
Overall survival
Week 8
Endpoint Evaluation
Week 8
Duration of AEs/SAEs
Severity of AEs/SAEs
Week 8
The time to objective disease progression
Month 5
Best overall response of confirmed PR or CR by independent radiology review
Month 5
Primary Endpoint: Efficacy
Month 5
Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy
Radiographic progression-free survival (rPFS)
Week 8
Incidence of AEs/SAEs
Week 8
Time to progression (TTP) based on independent radiology review

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

32 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Rampart Health, L.L.C.Lead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
David G Bostwick, M.D., M.B.A.Principal InvestigatorRampart Health

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to perform daily activities without assistance, with some limitations due to your medical condition.
You have tried all other standard treatments for your condition and they have not worked. You may also not be eligible for or have refused other available treatments due to concerns about side effects or poor outcomes.
You have been diagnosed with a solid cancer, and you need to provide your medical reports, including pathology specimens and imaging results, to Rampart Health for a review.
Your doctor thinks you are likely to live for at least 6 more months.
You have soft tissue abnormalities seen on imaging tests that suggest cancer has spread to other parts of your body. For patients with prostate cancer who undergo PSMA PET, only abnormalities that show up on both PET and CT or MRI scans will be considered signs of cancer spread.
Your imaging scans show that your lymph nodes have spread and any lymph node measuring 1.5 cm or more is considered to have cancer.
You agree to sign a document saying you understand the trial and give permission to participate.
You must be at least 18 years old to participate and sign the consent form.
Cancer has spread to your bones, as seen on imaging tests. If you had a bone scan or PET scan, either one can show the cancer spread. For prostate cancer patients who had a PSMA PET, only spots that look like cancer spread will count.
The medication used in this study may harm a developing baby. You must use effective birth control before starting the study, throughout the study, and for 120 days after the study ends.

Frequently Asked Questions

What is the aggregate amount of participants recruited for this trial?

"Affirmative. According to, the trial which debuted on May 19th 2021 is still enrolling participants. A total of 32 volunteers need to be brought in from a single site before its completion date (June 15th 2022)." - Anonymous Online Contributor

Unverified Answer

What health issues have been successfully managed through this therapy?

"Malignant melanoma of the skin is often managed with this particular treatment. Additionally, it has proven to be an efficacious modality for managing recurrent cervical cancer, leukemia, and refractory/relapsed mediastinal large B-cell lymphoma." - Anonymous Online Contributor

Unverified Answer

Is enrollment currently available for this clinical experiment?

" records indicate that the study, which was initially posted on May 19th 2021, is still actively recruiting patients for participation. The most recent update to this listing happened on June 15th 2022." - Anonymous Online Contributor

Unverified Answer

Has this regimen been granted regulatory authorization from the FDA?

"Our team at Power assigned this treatment a rating of 2 on the safety scale because it is currently in Phase 2, which means there is evidence that supports its security but no data has been collected regarding efficiency." - Anonymous Online Contributor

Unverified Answer

Are there any previous studies that have explored the efficacy of this treatment?

"As of now, 2059 trials are running to examine this particular treatment. Of these live tests, 310 have entered Phase 3. Most studies are conducted in Philadelphia; however, 82422 sites across the world offer clinical trials for this therapy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.